Divi's Laboratories Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Strong return on equity (ROE 16.5%)
- Efficient capital deployment (ROCE 22%)
- Virtually debt-free
Concerns
- Premium to sector peers (P/E 79.8x vs industry 50.2x)
- High premium to book value (P/B 15.1x)
Today's Price Action
The stock closed at ₹9,558.5 with zero percent change, matching the previous close. Trading volume today was 7,44,981 shares, identical to the 20‑day average, indicating that participation levels remain consistent.
Valuation Snapshot
Divi's Laboratories reports a trailing P/E of 79.8, considerably higher than the sector’s notional P/E of zero, reflecting a premium valuation relative to peers. The return on equity stands at 16.5 percent, suggesting efficient capital utilisation. A P/B of zero indicates that book value is negligible, emphasizing earnings as the primary valuation driver.
Key Levels to Watch
The price sits near the upper end of the 52‑week range, with the high of ₹10,000 acting as a strong ceiling and the low of ₹5,648 providing support. Open‑interest data from nearby options contracts cluster around ₹9,200 and ₹9,800, offering potential intraday reference points. Historical price action shows the stock respecting the ₹9,200 level on multiple pullbacks, while the ₹9,800 zone has acted as resistance in prior rallies.
Chart Pattern
Recent daily candles show a bullish Marubozu two days ago, a bearish engulfing six days ago, and a dragonfly doji eight days ago, all on the 1‑day timeframe. These formations illustrate alternating momentum and indecision within the short‑term price structure.
Data Summary
The latest figures display a market price of ₹9,558.5, a P/E of 79.8, a P/B of 0, and an ROE of 16.5 percent. Volume today equals the 20‑day average of 7,44,981 shares, and the 52‑week range spans ₹5,648 to ₹10,000. The trading activity remains aligned with the longer‑term average, and the metrics place the company in the higher‑multiple segment of the healthcare peer group. Market sentiment.
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
| DRREDDY Dr. Reddy's Laboratories Limited | ₹1,335 | ₹1.0L Cr | 36.6 | 2.87 | 11.2 | 13 | 0.19 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
DIVISLAB · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 51.92% | 51.92% | 51.89% | 51.89% | 51.89% | 51.89% |
| FII | 14.85% | 14.68% | 16.16% | 17.25% | 17.98% | 18.01% |
| DII | 21.78% | 22.10% | 21.66% | 20.98% | 20.44% | 20.63% |
| Public | 11.33% | 11.19% | 10.17% | 9.79% | 9.58% | 9.39% |
| Govt | 0.10% | 0.10% | 0.10% | 0.09% | 0.09% | 0.09% |
Corporate Events
To consider and approve the financial results for the period ended September 30, 2026
To consider and approve the financial results for the period ended Jun 30, 2026
Dividend - Rs 30 Per Share
To consider and approve the financial results for the period ended March 31, 2026 and dividend
Dividend - Rs 30 Per Share
Dividend - Rs 30 Per Share
Dividend - Rs 30 Per Share
Latest News
All newsDivi's Labs shares update post analyst meet
*Divi's Labs shares update post analyst meet* as the company released transcript from recent investor interaction. No major operational or financial updates were disclosed, keeping sentiment neutral. The event provided clarity on ongoing operations and management outlook. 📊 *STOCKS:* $DIVISLAB | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma
Divi's Labs shares copy of newspaper publication
*Divi's Labs shares copy of newspaper publication.* The company informed the exchange of a newspaper publication, a routine regulatory disclosure. No financial or operational details were provided in the filing. Such notices typically pertain to statutory announcements or investor communications. 📊 *STOCKS:* DIVISLAB | 🏢 *SECTOR:* Pharma | #LOWIMPACT #CorporateFiling
Divi's Labs announces AGM date and dividend record date
*Divi's Labs announces AGM date and dividend record date* — The company has published notice of its 36th Annual General Meeting and set a record date for dividend payout. This is part of routine corporate compliance. No financial surprises or strategic shifts were indicated. 📊 *STOCKS:* DIVISLAB | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Dividend
Divi's Labs announces dividend TDS details for FY26
*Divi's Laboratories announces dividend TDS details for FY26.* The company has informed the exchange about the deduction of income tax at source from dividend payments for FY2025-26. This is a routine compliance disclosure related to dividend disbursement. No financial impact on operations or earnings is expected. 📊 *STOCKS:* DIVISLAB | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Dividend
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2.6K Cr 4.1% | ₹2.7K Cr 12.7% | ₹2.4K Cr 6.8% | ₹2.6K Cr 11.5% | ₹2.3K Cr 0.8% | ₹2.3K Cr 10.4% | ₹2.1K Cr 8.0% | ₹2.3K Cr |
| Op. Profit | ₹890 Cr 0.2% | ₹888 Cr 21.8% | ₹729 Cr 17.7% | ₹886 Cr 19.2% | ₹743 Cr 3.8% | ₹716 Cr 15.1% | ₹622 Cr 14.9% | ₹731 Cr |
| OPM | 34.0% 3.0% | 33.0% 10.0% | 30.0% 11.8% | 34.0% 6.3% | 32.0% 3.2% | 31.0% 6.9% | 29.0% 9.4% | 32.0% |
| Net Profit | ₹583 Cr 15.4% | ₹689 Cr 26.4% | ₹545 Cr 17.7% | ₹662 Cr 12.4% | ₹589 Cr 15.5% | ₹510 Cr 18.6% | ₹430 Cr 20.1% | ₹538 Cr |
| EPS (₹) | 21.96 15.4% | 25.95 26.4% | 20.53 17.7% | 24.94 12.4% | 22.19 15.5% | 19.21 18.6% | 16.2 20.1% | 20.27 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹10.6K Cr 12.8% | ₹9.4K Cr 19.3% | ₹7.8K Cr 1.0% | ₹7.8K Cr 13.3% | ₹9.0K Cr 28.6% | ₹7.0K Cr 29.2% | ₹5.4K Cr 9.1% | ₹4.9K Cr 27.1% | ₹3.9K Cr 4.3% | ₹4.1K Cr |
| Expenses | ₹7.1K Cr 11.4% | ₹6.4K Cr 13.3% | ₹5.6K Cr 4.4% | ₹5.4K Cr 6.3% | ₹5.1K Cr 23.7% | ₹4.1K Cr 15.0% | ₹3.6K Cr 16.1% | ₹3.1K Cr 17.2% | ₹2.6K Cr 0.3% | ₹2.6K Cr |
| Op. Profit | ₹3.4K Cr 15.8% | ₹3.0K Cr 34.5% | ₹2.2K Cr 6.8% | ₹2.4K Cr 39.0% | ₹3.9K Cr 35.5% | ₹2.9K Cr 57.0% | ₹1.8K Cr 2.6% | ₹1.9K Cr 47.7% | ₹1.3K Cr 12.5% | ₹1.4K Cr |
| OPM | 33.0% 3.1% | 32.0% 14.3% | 28.0% 9.7% | 31.0% 27.9% | 43.0% 4.9% | 41.0% 20.6% | 34.0% 10.5% | 38.0% 15.2% | 33.0% 8.3% | 36.0% |
| Other Income | ₹433 Cr 24.4% | ₹348 Cr 3.9% | ₹335 Cr 2.6% | ₹344 Cr 207.1% | ₹112 Cr 96.5% | ₹57 Cr 69.4% | ₹186 Cr 20.8% | ₹154 Cr 43.9% | ₹107 Cr 48.6% | ₹72 Cr |
| Interest | ₹24 Cr 700.0% | ₹3 Cr 25.0% | ₹4 Cr 100.0% | ₹2 Cr 0.0% | ₹2 Cr 0.0% | ₹2 Cr 71.4% | ₹7 Cr 40.0% | ₹5 Cr 150.0% | ₹2 Cr 33.3% | ₹3 Cr |
| Depreciation | ₹463 Cr 15.2% | ₹402 Cr 6.3% | ₹378 Cr 10.2% | ₹343 Cr 9.9% | ₹312 Cr 21.9% | ₹256 Cr 37.6% | ₹186 Cr 10.1% | ₹169 Cr 19.0% | ₹142 Cr 15.4% | ₹123 Cr |
| PBT | ₹3.4K Cr 16.2% | ₹2.9K Cr 34.8% | ₹2.2K Cr 8.7% | ₹2.4K Cr 35.7% | ₹3.7K Cr 38.2% | ₹2.7K Cr 46.6% | ₹1.8K Cr 1.9% | ₹1.9K Cr 50.7% | ₹1.2K Cr 11.8% | ₹1.4K Cr |
| Tax % | 24.0% 4.0% | 25.0% 3.8% | 26.0% 13.0% | 23.0% 15.0% | 20.0% 23.1% | 26.0% 8.3% | 24.0% 11.1% | 27.0% 6.9% | 29.0% 20.8% | 24.0% |
| Net Profit | ₹2.6K Cr 17.2% | ₹2.2K Cr 36.9% | ₹1.6K Cr 12.2% | ₹1.8K Cr 38.4% | ₹3.0K Cr 49.2% | ₹2.0K Cr 44.1% | ₹1.4K Cr 1.8% | ₹1.4K Cr 54.3% | ₹877 Cr 17.3% | ₹1.1K Cr |
| EPS (₹) | 96.73 17.2% | 82.53 36.9% | 60.27 12.3% | 68.69 38.4% | 111.52 49.2% | 74.75 44.2% | 51.85 1.7% | 50.96 54.2% | 33.04 17.3% | 39.95 |
| Div Payout | 31.0% 13.9% | 36.0% 28.0% | 50.0% 13.6% | 44.0% 63.0% | 27.0% 0.0% | 27.0% 12.9% | 31.0% 0.0% | 31.0% 3.3% | 30.0% 20.0% | 25.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||||
| Equity Capital | ₹53 Cr 0.0% | ₹53 Cr 0.0% | ₹53 Cr 0.0% | ₹53 Cr 0.0% | ₹53 Cr 0.0% | ₹53 Cr 0.0% | ₹53 Cr 0.0% | ₹53 Cr 0.0% | ₹53 Cr 0.0% | ₹53 Cr |
| Reserves | ₹15.4K Cr 3.0% | ₹14.9K Cr 10.3% | ₹13.5K Cr 6.3% | ₹12.7K Cr 8.9% | ₹11.7K Cr 26.3% | ₹9.2K Cr 27.4% | ₹7.3K Cr 5.1% | ₹6.9K Cr 17.6% | ₹5.9K Cr 10.7% | ₹5.3K Cr |
| Borrowings | ₹90 Cr 2150.0% | ₹4 Cr 33.3% | ₹3 Cr 0.0% | ₹3 Cr 25.0% | ₹4 Cr 20.0% | ₹5 Cr 87.2% | ₹39 Cr 63.2% | ₹106 Cr 68.3% | ₹63 Cr 75.0% | ₹36 Cr |
| Other Liabilities | ₹2.6K Cr 35.9% | ₹1.9K Cr 3.3% | ₹1.9K Cr 14.0% | ₹1.7K Cr 1.6% | ₹1.6K Cr 10.7% | ₹1.5K Cr 24.3% | ₹1.2K Cr 21.6% | ₹973 Cr 22.1% | ₹797 Cr 4.6% | ₹762 Cr |
| Total Liabilities | ₹18.2K Cr 7.3% | ₹16.9K Cr 9.5% | ₹15.5K Cr 7.2% | ₹14.4K Cr 8.0% | ₹13.4K Cr 24.0% | ₹10.8K Cr 26.3% | ₹8.5K Cr 6.2% | ₹8.0K Cr 18.4% | ₹6.8K Cr 10.2% | ₹6.2K Cr |
Assets | ||||||||||
| Fixed Assets | ₹5.7K Cr 4.3% | ₹5.4K Cr 14.8% | ₹4.7K Cr 0.3% | ₹4.7K Cr 9.2% | ₹4.3K Cr 16.8% | ₹3.7K Cr 33.1% | ₹2.8K Cr 33.2% | ₹2.1K Cr 4.6% | ₹2.0K Cr 28.0% | ₹1.6K Cr |
| CWIP | ₹2.0K Cr 98.6% | ₹1.0K Cr 31.4% | ₹778 Cr 267.0% | ₹212 Cr 54.9% | ₹470 Cr 33.9% | ₹711 Cr 22.7% | ₹920 Cr 87.0% | ₹492 Cr 310.0% | ₹120 Cr 73.0% | ₹444 Cr |
| Investments | ₹67 Cr 3.1% | ₹65 Cr 20.7% | ₹82 Cr 6.5% | ₹77 Cr 6.9% | ₹72 Cr | ₹0 Cr 100.0% | ₹971 Cr 50.1% | ₹1.9K Cr 3.0% | ₹1.9K Cr 15.8% | ₹1.6K Cr |
| Other Assets | ₹10.4K Cr 0.2% | ₹10.4K Cr 5.4% | ₹9.9K Cr 4.8% | ₹9.4K Cr 10.8% | ₹8.5K Cr 33.6% | ₹6.4K Cr 64.7% | ₹3.9K Cr 9.9% | ₹3.5K Cr 26.3% | ₹2.8K Cr 10.3% | ₹2.5K Cr |
| Total Assets | ₹18.2K Cr 7.3% | ₹16.9K Cr 9.5% | ₹15.5K Cr 7.2% | ₹14.4K Cr 8.0% | ₹13.4K Cr 24.0% | ₹10.8K Cr 26.3% | ₹8.5K Cr 6.2% | ₹8.0K Cr 18.4% | ₹6.8K Cr 10.2% | ₹6.2K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹1.7K Cr 31.1% | ₹1.3K Cr 48.7% | ₹2.5K Cr 28.7% | ₹1.9K Cr 1.8% | ₹1.9K Cr 60.1% | ₹1.2K Cr 27.5% | ₹954 Cr 22.9% | ₹776 Cr 32.5% | ₹1.1K Cr 10.8% | ₹1.0K Cr |
| Investing CF | ₹-804 Cr 198.9% | ₹-269 Cr 90.1% | ₹-2.7K Cr 23.4% | ₹-2.2K Cr 3026.7% | ₹75 Cr 190.4% | ₹-83 Cr 87.9% | ₹-685 Cr 43.3% | ₹-478 Cr 58.1% | ₹-1.1K Cr 180.8% | ₹-406 Cr |
| Financing CF | ₹-799 Cr 0.0% | ₹-799 Cr 0.3% | ₹-797 Cr 49.8% | ₹-532 Cr 1420.0% | ₹-35 Cr 96.8% | ₹-1.1K Cr 343.5% | ₹-246 Cr 21.7% | ₹-314 Cr 15800.0% | ₹2 Cr 100.3% | ₹-631 Cr |
| Net Cash Flow | ₹50 Cr 74.1% | ₹193 Cr 118.5% | ₹-1.0K Cr 28.1% | ₹-816 Cr 141.1% | ₹2.0K Cr 4746.3% | ₹41 Cr 78.3% | ₹23 Cr 235.3% | ₹-17 Cr 230.8% | ₹13 Cr | ₹0 Cr |
| Free Cash Flow | ₹215 Cr 16.7% | ₹258 Cr 87.0% | ₹2.0K Cr 65.7% | ₹1.2K Cr 15.6% | ₹1.0K Cr 3042.4% | ₹33 Cr 85.1% | ₹221 Cr 56.0% | ₹502 Cr 35.1% | ₹774 Cr 20.6% | ₹642 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 106d 6.0% | 100d 19.0% | 84d 15.2% | 99d 12.5% | 88d 8.3% | 96d 11.6% | 86d 9.5% | 95d 17.3% | 81d 4.7% | 85d |
| Inventory Days | 311d 14.6% | 364d 3.4% | 352d 3.2% | 341d 3.6% | 329d 4.1% | 316d 8.9% | 347d 10.5% | 314d 2.3% | 307d 4.8% | 293d |
| Days Payable | 88d 6.4% | 94d 5.6% | 89d 7.3% | 96d 17.9% | 117d 17.0% | 100d 4.2% | 96d 0.0% | 96d 7.7% | 104d 85.7% | 56d |
| Cash Conv. Cycle | 330d 10.8% | 370d 6.6% | 347d 0.9% | 344d 14.7% | 300d 3.8% | 312d 7.1% | 336d 7.3% | 313d 10.2% | 284d 11.8% | 322d |
| Working Capital Days | 192d 6.8% | 206d 9.6% | 188d 6.2% | 177d 16.4% | 152d 15.6% | 180d 6.5% | 169d 4.0% | 176d 19.7% | 147d 7.0% | 158d |
| ROCE | 20.0% 25.0% | 16.0% 15.8% | 19.0% 45.7% | 35.0% 9.4% | 32.0% 28.0% | 25.0% 13.8% | 29.0% 31.8% | 22.0% 24.1% | 29.0% 19.4% | 36.0% |
Source: Screener.in · Lower days = better efficiency
Deep Dive Analysis
About Divi's Laboratories Limited
Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients[1]
HealthcarePharmaceuticals & Biotechnology